Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 721,002 shares of the company's stock, valued at approximately $12,949,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.65% of Amylyx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently made changes to their positions in the company. Meeder Asset Management Inc. purchased a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $25,000. KBC Group NV purchased a new position in Amylyx Pharmaceuticals in the 1st quarter worth $26,000. California State Teachers Retirement System purchased a new position in Amylyx Pharmaceuticals in the 2nd quarter worth $28,000. State of Wyoming bought a new stake in Amylyx Pharmaceuticals in the second quarter worth $40,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Amylyx Pharmaceuticals by 954.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company's stock worth $47,000 after purchasing an additional 3,493 shares during the last quarter. 95.84% of the stock is currently owned by institutional investors.
Amylyx Pharmaceuticals Stock Down 1.8%
Shares of Amylyx Pharmaceuticals stock opened at $37.46 on Wednesday. The company's fifty day simple moving average is $21.28 and its two-hundred day simple moving average is $17.03. Amylyx Pharmaceuticals, Inc. has a 12-month low of $8.48 and a 12-month high of $41.14. The firm has a market cap of $4.17 billion, a PE ratio of -26.20 and a beta of -0.21.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). As a group, sell-side analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current fiscal year.
Insider Transactions at Amylyx Pharmaceuticals
In related news, insider Gina Mazzariello sold 15,000 shares of the business's stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the transaction, the insider owned 194,090 shares in the company, valued at $3,555,728.80. The trade was a 7.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.90% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the company. Mizuho raised their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an "outperform" rating in a research note on Tuesday, August 18th. HC Wainwright lifted their price objective on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, August 18th. Guggenheim boosted their target price on Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday, August 19th. Wolfe Research upgraded Amylyx Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 17th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Amylyx Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $36.25.
View Our Latest Analysis on Amylyx Pharmaceuticals
Amylyx Pharmaceuticals Company Profile
(
Free Report)
See Also
Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
